RxSight, Inc.
RXST
$13.76
$0.453.38%
NASDAQ
| 03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
|---|---|---|---|---|---|
| Revenue | 46.69% | 57.08% | 67.51% | 71.90% | 75.67% |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | 46.69% | 57.08% | 67.51% | 71.90% | 75.67% |
| Cost of Revenue | 12.72% | 16.06% | 22.49% | 22.03% | 24.97% |
| Gross Profit | 66.32% | 84.03% | 101.70% | 117.07% | 129.43% |
| SG&A Expenses | 30.35% | 35.49% | 35.85% | 34.59% | 33.04% |
| Depreciation & Amortization | -- | -- | -- | -- | -- |
| Other Operating Expenses | -- | -- | -- | -- | -- |
| Total Operating Expenses | 24.48% | 27.03% | 27.95% | 26.37% | 26.72% |
| Operating Income | 22.66% | 26.41% | 27.93% | 26.54% | 20.35% |
| Income Before Tax | 40.44% | 43.60% | 44.23% | 38.14% | 28.70% |
| Income Tax Expenses | 103.45% | 150.00% | -53.49% | -38.71% | 480.00% |
| Earnings from Continuing Operations | 40.34% | 43.52% | 44.23% | 38.14% | 28.66% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | 40.34% | 43.52% | 44.23% | 38.14% | 28.66% |
| EBIT | 22.66% | 26.41% | 27.93% | 26.54% | 20.35% |
| EBITDA | 22.56% | 27.66% | 30.45% | 28.89% | 22.48% |
| EPS Basic | 46.68% | 49.93% | 52.45% | 49.16% | 42.91% |
| Normalized Basic EPS | 44.55% | 48.18% | 51.02% | 50.89% | 45.22% |
| EPS Diluted | 46.68% | 49.93% | 52.45% | 49.16% | 42.91% |
| Normalized Diluted EPS | 44.55% | 48.18% | 51.02% | 50.89% | 45.22% |
| Average Basic Shares Outstanding | 11.29% | 12.84% | 16.38% | 20.64% | 24.48% |
| Average Diluted Shares Outstanding | 11.29% | 12.84% | 16.38% | 20.64% | 24.48% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |